Sareum Holdings PLC

(“Sareum” or the "Company")

Sareum Launches New Website

Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development business, is pleased to announce today the launch of its new website, &

The website has been designed with an updated look that reflects the Company’s progress towards first-in-human clinical trials. It also features simplified navigation and compatibility with mobile devices.

Dr Tim Mitchell, CEO of Sareum, commented: “We hope you enjoy browsing our new site. We believe it provides an excellent platform for Sareum to communicate with its investors and business partners.”

For further information, please contact:

Sareum Holdings PLC

Tim Mitchell
Tel: 01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / Nick Prowting
Tel: 020 7220 1666

Hybridan LLP (Co-Broker)

Claire Noyce / William Lynne
Tel: 020 3713 4580

The Communications Portfolio (Public Relations)

Ariane Comstive
Tel: 07785 922 354

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit